Home > AlchePharma in the News




National News of our past product research and development:

AlchePharma Launches Tripeptide-2X with AmealPeptide®, for Cardiovascular Health

The AmealPeptide in AlchePharma's TriPeptide-2x works by inhibiting an enzyme that leads to the constriction of blood vessels.* This vasodilating action is believed to be at least partly responsible for AmealPeptide's clinically documented effect on blood pressure.*

SANTA MARIA, Calif., Jan. 29, 2016 /PRNewswire-iReach/ -- AlchePharma, a division of Vitamin and Herb Stores, is launching TriPeptide- 2X featuring AmealPeptide®, a clinically tested, proprietary ingredient derived from casein (a milk protein). Supported by more than 30 published studies — including over a dozen double-blind, placebo-controlled human clinical trials — AmealPeptide helps maintain both systolic and diastolic blood pressure already within healthy limits and promotes arterial elasticity.*

Photo - http://photos.prnewswire.com/prnh/20160128/327244

The AmealPeptide in AlchePharma's TriPeptide-2X works by inhibiting an enzyme that leads to the constriction of blood vessels.* This vasodilating action is believed to be at least partly responsible for AmealPeptide's clinically documented effect on blood pressure.*

Why Tripeptides Work

In order for a peptide to be absorbed into the gastrointestinal tract, it must contain three amino acids or less. If a peptide has more than three amino acids, it is very poorly absorbed by the human body. Studies have shown that AmealPeptide, with 2 tripeptides, is able to block ACE reactions and help maintain healthy blood pressure.*

AmealPeptide could help support:

  • Blood Circulation*
  • Blood Pressure*
  • Cardiovascular Health*
  • Heart Health*
  • Stress Management*

AlchePharma has initiated international distribution of TriPeptide-2X as of January 2016.

About AlchePharma:

AlchePharma was started with the intention of developing well studied nutraceuticals for the medical community and the public. Our desire is to build a strategic bridge to the medical scientific community in regards GRAS ingredients. Components that have the potential to be of value, as an additional to tool set for the medical community and the public. We believe this requires a methodical approach to what is efficacious with a solid risk to benefit ratio. Leading to our primary objective of being a viable trusted resource to the medical community.

*These statements have not been evaluated by the Food & Drug Administration. This ingredient is not intended to diagnose, treat, cure or prevent any disease.

Media Relations: Jade Butlig

Vh30jade@gmail.com

Distribution Manager: Paula Mowry

Vh32paula@gmail.com

Product Development: Ralph Turchiano

Vh39ralph@gmail.com

Administration: Betsy Arrastia

Vh33Betsy@gmail.com

AlchePharma
1130 E. Clark Ave. #120
Santa Maria, CA 93455
805 314 2347
www.AlchePharma.com
support@AlchePharma.com

Media Contact: Paula Mowry, AlchePharma, 805-314-2347, vh32paula@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE AlchePharma






New products from AlchePharma, that are being either researched or are in production